Corbus Pharmaceuticals Holdings, Inc. filings document a clinical-stage biotechnology issuer focused on oncology and obesity. The record includes Form 8-K material-event reports for clinical and regulatory disclosures involving CRB-701 and CRB-913, Regulation FD corporate presentations and risk language tied to product development, trial timelines and business strategy.
Proxy and governance filings cover board matters, executive compensation, equity awards, employment agreements and officer or director changes. The filings also provide formal disclosure categories for operating and financial results and the governance framework supporting the company’s drug-development pipeline.
Corbus Pharmaceuticals Holdings, Inc. is asking stockholders to vote at a virtual annual meeting on May 13, 2026. Proposals include electing six directors, approving an amendment to the 2024 Equity Compensation Plan to raise the share reserve by 3,000,000 shares to 5,000,000 shares, ratifying EisnerAmper LLP as auditor for 2026, and advisory votes on executive pay and how often to hold future say‑on‑pay votes, with the Board recommending an annual frequency. As of March 23, 2026, 17,736,464 shares of common stock were outstanding and entitled to one vote per share. The proxy also details 2025 executive pay, governance practices, board committee composition and activity, and pay‑versus‑performance data showing a 2025 net loss alongside higher cumulative total shareholder return.
Corbus Pharmaceuticals Holdings, Inc. registers an aggregate $300,000,000 shelf to offer common stock, preferred stock, warrants, debt securities, subscription rights and units under a shelf registration statement.
The prospectus states the offerings may be made separately or together in one or more offerings and that aggregate public offering price will not exceed $300,000,000. The document lists that 17,736,464 shares of common stock were issued and outstanding as of March 6, 2026.
Corbus Pharmaceuticals Holdings, Inc. files a registration statement to offer up to $300,000,000 of securities under a shelf prospectus. The shelf permits the company to issue common stock, preferred stock, warrants, debt securities, subscription rights and units from time to time, in one or more offerings.
The prospectus states the aggregate public offering price will not exceed $300,000,000 and that specific terms, listing information and use of proceeds for each issuance will be provided in future prospectus supplements. The prospectus also discloses 17,736,464 shares of common stock issued and outstanding as of close of business on March 6, 2026.
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotech focused on oncology and obesity, reporting a net loss of $78.5 million in 2025 and cumulative losses of $555.4 million. Cash, cash equivalents and investments were $163.3 million, supporting development but not yet reaching profitability.
The lead oncology asset, CRB-701, a Nectin-4–targeting antibody-drug conjugate, showed encouraging Phase 1/2 activity across head and neck, cervical and urothelial cancers, with notable objective response and disease control rates and a differentiated emerging safety and pharmacokinetic profile versus PADCEV®. The FDA granted fast track designations in relapsed or refractory metastatic cervical cancer and in certain head and neck cancers, and the company plans FDA discussions on registrational study designs in 2026.
In obesity, oral CB1 inverse agonist CRB-913 completed a Phase 1a SAD/MAD trial with no serious adverse events, minimal gastrointestinal effects and a mean 2.9% placebo‑adjusted weight loss by Day 14 in an obese cohort at 150 mg once daily. A 240‑subject Phase 1b CANYON‑1 study began in late 2025. The earlier oncology antibody CRB‑601 has been deprioritized. Corbus increased 2025 research and development spending to $70.1 million and raised additional capital through an at-the-market program and a $70.2 million underwritten equity offering.
Corbus Pharmaceuticals Holdings, Inc. reported a larger net loss as it advanced its oncology and obesity pipeline and strengthened its balance sheet. Net loss was $20.6 million, or $1.25 per share, for Q4 2025, compared with $9.5 million, or $0.78 per share, a year earlier, driven mainly by higher clinical development spending.
For full-year 2025, net loss was $78.5 million versus $40.2 million in 2024, as research and development expenses more than doubled to $70.1 million. The company ended 2025 with $163.3 million in cash, cash equivalents and investments, and stated this is expected to fund operations into 2028.
Corbus highlighted promising clinical signals from its three key programs. CRB-701, a next‑generation Nectin‑4 antibody‑drug conjugate with FDA Fast Track designations in head and neck squamous cell carcinoma and cervical cancer, showed encouraging Phase 1/2 response rates and a favorable emerging safety profile, with additional monotherapy data and a registrational study update planned for mid‑2026.
CRB-913, an oral CB1 inverse agonist for obesity, produced placebo‑adjusted weight loss of 2.9% over 14 days with favorable gastrointestinal and neuropsychiatric assessments, and a 12‑week, 240‑patient Phase 1b study is expected to complete in summer 2026. The company completed a $75 million public offering in Q4 2025, which it says extended its cash runway into 2028 while it focuses on oncology and obesity opportunities.
Corbus Pharmaceuticals Holdings, Inc. Chief Medical Officer Dominic Smethurst reported an open-market sale of 6,097 shares of common stock at a weighted average price of $8.2994 per share. The sale was mandated to cover tax withholding on vesting RSUs and was not a discretionary trade. After this transaction, he directly holds 89,790 shares, including 73,765 unvested RSUs that remain subject to their vesting schedules.
CRBP insider filed a Form 144 to sell Common Stock. The notice lists proposed brokered sales through Stifel Nicolaus & Company and records Restricted Stock Units of 12,500 dated 02/28/2026. The filing also discloses a prior sale of 3,285 shares on 02/03/2026.
Corbus Pharmaceuticals Holdings furnished an updated investor presentation outlining its cash position, pipeline and upcoming milestones. The company reported $173M in cash, cash equivalents and investments as of November 3, 2025, with approximately 17 common shares issued and outstanding and about 20 fully diluted shares.
The presentation highlights three key programs. CRB-701, a next‑generation Nectin‑4 antibody–drug conjugate, showed objective response rates up to 47.6% in head and neck cancer and 55.6% in cervical cancer at the 3.6 mg/kg dose in early studies, with lower rates of peripheral neuropathy and rash than PADCEV in referenced datasets. CRB-913, a peripherally restricted CB1 inverse agonist for obesity, produced 2.9% placebo‑adjusted weight loss by day 14 in a 150 mg multiple‑dose cohort, with no reported nausea, vomiting or constipation in the summarized data.
CRB-601, an anti‑αvβ8 antibody targeting TGFβ activation in solid tumors, is in early clinical development. Corbus outlines planned milestones into 2026, including a Phase 2/3 registrational study for CRB‑701 in head and neck cancer, additional combination data with pembrolizumab, and completion of a 240‑patient Phase 1b obesity study for CRB‑913.
Corbus Pharmaceuticals Holdings, Inc.’s Chief Operating Officer Ian Hodgson reported an open-market sale of 847 shares of common stock at a weighted-average price of $7.383 per share. According to the disclosure, this sale was mandated as a “sell to cover” transaction to satisfy tax withholding obligations tied to the vesting and settlement of restricted stock units and was not a discretionary trade.
After the transaction, Hodgson directly held 51,080 shares, which the disclosure notes includes 46,362 unvested restricted stock units that continue to vest under their existing schedules.